ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0028

Adenosine Deaminase 2 Is Expressed as a Short Isoform Lacking Deaminase Activity in the Endothelium: Implications for DADA2 Vasculitis

Andrew Porter1, Robert Maughan1, Charis Pericleous1, Lida Kabir1, Richard Stratton2, Dorian Haskard1, Pui Lee3, Taryn Youngstein1 and Justin Mason1, 1National Heart & Lung Institute, Imperial College London, London, United Kingdom, 2University College London, London, United Kingdom, 3Division of Immunology, Boston Children's Hospital, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, genetics, Non-coding RNA, Pediatric rheumatology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive condition caused by biallelic variants in the Adenosine deaminase 2 (ADA2) gene. Clinical manifestations are broad, but a vasculitis phenotype is widely recognised. Although ADA2 expression is conventionally associated with myeloid cells, a recent report identified expression in endothelial cells (ECs) and demonstrated Interferon (IFN) β induction in the absence of ADA2. The current study aimed to investigate the expression and role of ADA2 in the endothelium.

Methods: ADA2 transcript expression was explored across different tissues and cell types using Blueprint, GTEX and in-house short and long read RNA-seq datasets. Findings were validated by qRT-PCR, immunoblot and an ADA2 activity assay in primary human umbilical vein and aortic ECs (HUVEC, HAEC) and the pro-monocytic cell line U937.

Endothelial colony forming cells (ECFC) were cultured from peripheral blood mononuclear cells (PBMCs) isolated from patients with DADA2 and healthy donors, following our established protocols.

Results: We identified 3 human ADA2 isoforms: ADA2 201 and 203, the classically described myeloid derived isoforms (511 amino acids, aa) and ADA2 202 which was predicted to encode a shorter protein lacking a signal peptide and part of the deaminase domain (270 aa) (Fig 1A). In contrast to 201 and 203, the 202 isoform appears widely expressed across tissue types but absent from immune cells (Fig 1B & C).

Analysis of RNA-seq data identified 202 as the sole ADA2 transcript expressed in ECs (Fig 2A). This was confirmed by qPCR using transcript-specific primers: 202 was the predominant isoform in ECs and 201/203 in PBMCs and U937 (Fig 2B).

Despite the presence of ADA2 202 mRNA, no protein or deaminase activity were detected in HUVEC or HAEC lysates or supernatants (Fig 2C). Overexpression of 201 isoform demonstrated deaminase activity and protein secretion as expected; in contrast 202 was enzymatically inactive, not secreted and retained in the insoluble protein fraction.

Since 202 was expressed at the mRNA but not protein level, we explored a possible regulatory function by siRNA knockdown (KD) in HUVEC (90% KD achieved). ADA2 KD resulted in dysregulation of 352 genes and enriched inflammatory (IFN, TNF), coagulant and apoptotic signalling suggesting an important role for 202 in endothelial homeostasis (Fig 3B).

Consistent with this, initial ECFC analysis demonstrated a lower proliferative and more inflammatory phenotype in DADA2 compared to healthy donor ECFC, characterised by increased ICAM-1, VCAM-1 and IFN-related gene expression (n=4 per group).

Conclusion: Endothelial ADA2 is expressed exclusively as the shortened 202 transcript but its protein form is undetectable. Artificially overexpressed 202 accumulated in the insoluble protein fraction, lacked deaminase activity and thus appeared non-functional. ADA2 knockdown in ECs led to upregulation of inflammatory apoptotic gene expression, potentially indicating a role for 202 in endothelial homeostasis as a non-coding RNA. Given its widespread tissue expression, genetic variants affecting 202 could have implications for understanding the heterogenous manifestations of DADA2.

Supporting image 1

Figure 1A – 3 ADA2 isoforms exon map.
Figure 1B – Blueprint blood database demonstrating ADA2 isoform expression in blood cells.
Figure 1C – GTEX data demonstrating ADA2 isoform expression in tissues.

Supporting image 2

Figure 2A – signal plot from our own RNAseq in Human Umbilical Vein Endothelial Cells (HUVEC) showing ADA2 202 transcript expression.
Figure 2B – RT-qPCR demonstrating expression of ADA2 202 and ADA2 201/203 in different cell types. Human Dermal Vascular Endothelial Cells (HDVEC), Human Umbilical Vein Endothelial Cells (HUVEC), Peripheral Blood Mononuclear cells (PBMC), THP1 – monocyte cell line, U937 – pro-monocytic cell line.
Figure 2C – ADA2 enzymatic activity in lysate and supernatant from U937 and HUVEC

Supporting image 3

Figure 3A – Volcano plot demonstrating differentially expressed genes with ADA2 KD in HUVEC.
Figure 3B – Table demonstrating gene set enrichment pathway analysis. NES – normalised enrichment score. FDR – false discovery rate.


Disclosures: A. Porter: None; R. Maughan: None; C. Pericleous: None; L. Kabir: None; R. Stratton: Aurinia Pharmaceuticals Inc., 5, Riptide Bioscience Inc., 5; D. Haskard: None; P. Lee: None; T. Youngstein: None; J. Mason: None.

To cite this abstract in AMA style:

Porter A, Maughan R, Pericleous C, Kabir L, Stratton R, Haskard D, Lee P, Youngstein T, Mason J. Adenosine Deaminase 2 Is Expressed as a Short Isoform Lacking Deaminase Activity in the Endothelium: Implications for DADA2 Vasculitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/adenosine-deaminase-2-is-expressed-as-a-short-isoform-lacking-deaminase-activity-in-the-endothelium-implications-for-dada2-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-deaminase-2-is-expressed-as-a-short-isoform-lacking-deaminase-activity-in-the-endothelium-implications-for-dada2-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology